Rx Sight, Inc. RXST
We take great care to ensure that the data presented and summarized in this overview for RxSight, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RXST
View all-
Black Rock Inc. New York, NY2.11MShares$128 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI1.9MShares$115 Million0.15% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ1.77MShares$107 Million0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.52MShares$92.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.13MShares$68.3 Million0.0% of portfolio
-
Summit Partners Public Asset Management, LLC Boston, MA783KShares$47.5 Million1.43% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD772KShares$46.8 Million0.02% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M770KShares$46.7 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA769KShares$46.6 Million0.01% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL745KShares$45.2 Million0.01% of portfolio
Latest Institutional Activity in RXST
Top Purchases
Top Sells
About RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Insider Transactions at RXST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 03
2024
|
Ronald M Md Kurtz President & CEO |
SELL
Open market or private sale
|
Indirect |
40,000
-4.97%
|
$2,400,000
$60.15 P/Share
|
|
May 01
2024
|
Shelley B Thunen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-21.42%
|
$520,000
$52.86 P/Share
|
|
May 01
2024
|
Shelley B Thunen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,247
+29.98%
|
$153,705
$15.6 P/Share
|
|
Apr 01
2024
|
Shelley B Thunen Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
20,000
-16.33%
|
$1,000,000
$50.33 P/Share
|
|
Mar 01
2024
|
Shelley B Thunen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-16.15%
|
$560,000
$56.12 P/Share
|
|
Mar 01
2024
|
Shelley B Thunen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+29.68%
|
$150,000
$15.6 P/Share
|
|
Feb 16
2024
|
Ilya Goldshleger Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-14.8%
|
$550,000
$55.5 P/Share
|
|
Feb 16
2024
|
Ilya Goldshleger Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+21.52%
|
$230,000
$23.04 P/Share
|
|
Feb 15
2024
|
Ilya Goldshleger Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-14.8%
|
$530,000
$53.5 P/Share
|
|
Feb 15
2024
|
Ilya Goldshleger Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+21.52%
|
$230,000
$23.04 P/Share
|
|
Feb 14
2024
|
Ilya Goldshleger Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,000
-15.89%
|
$260,000
$52.0 P/Share
|
|
Feb 14
2024
|
Ilya Goldshleger Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+13.71%
|
$115,000
$23.04 P/Share
|
|
Feb 14
2024
|
Bakker Juliet Tammenoms |
BUY
Open market or private purchase
|
Direct |
4,000
+11.82%
|
$204,000
$51.29 P/Share
|
|
Feb 12
2024
|
Bakker Juliet Tammenoms |
BUY
Open market or private purchase
|
Direct |
4,000
+13.4%
|
$200,000
$50.38 P/Share
|
|
Feb 09
2024
|
Ilya Goldshleger Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
10,365
-15.22%
|
$518,250
$50.75 P/Share
|
|
Feb 09
2024
|
Ilya Goldshleger Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,365
+13.19%
|
$207,300
$20.97 P/Share
|
|
Feb 06
2024
|
Shelley B Thunen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,875
-53.69%
|
$746,125
$47.47 P/Share
|
|
Feb 06
2024
|
Shelley B Thunen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,875
+34.94%
|
$222,250
$14.95 P/Share
|
|
Feb 05
2024
|
Jesse Anderson Corley |
BUY
Bona fide gift
|
Indirect |
53,967
+18.38%
|
-
|
|
Feb 05
2024
|
Jesse Anderson Corley |
SELL
Bona fide gift
|
Indirect |
7,083
-100.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 45.8K shares |
|---|---|
| Other acquisition or disposition | 336K shares |
| Open market or private purchase | 8K shares |
| Bona fide gift | 54K shares |
| Exercise of conversion of derivative security | 227K shares |
| Bona fide gift | 57K shares |
|---|---|
| Other acquisition or disposition | 3.01M shares |
| Open market or private sale | 1.62M shares |